As of April 2024, BioNotus is GLP-certified by the Belgian OECD authorities, both for LC-MSMS-based bioanalysis and non-compartmental PK analysis. Contact us for your most challenging bioanalysis and preclincal drug development projects.
BioNotus proudly sponsors the first OSP community conference in Basel, 7-8 Oct 2024!
Drugs and Biomarkers
Bioanalysis encompasses the absolute and reproducible quantification of drugs and their metabolites as well as biomarkers in a biological matrix (e.g. plasma, urine, saliva,...)
Modelling & Simulation
Computational approaches enable prediction of individualised dosing and elucidation of underlying mechanisms relating to pharmacokinetics, efficacy and toxicity
Early PK predictions
In vitro models of liver, lung, kidney, intestine, breast and brain support determination of drug-specific PK parameters from the drug discovery stage onwards.
Fit for purpose is our DNA
Research Question
...identifies the specific objectives and drives the project flow.
Context-of-use validation
...for cost-efficient and sustainable quality management.
Small to large sample sets
...to draw the best possible conclusions.
EMA, FDA and ICH guidelines
...to meet regulatory guidelines.
Iterative integration
...of bioanalysis and PMX to turn data into actionable insights.
Diverse partner network
...to always select the best possible team and solution.